Division of Rheumatology, Department of Pediatrics, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada.
Curr Rheumatol Rep. 2011 Jun;13(3):216-24. doi: 10.1007/s11926-011-0167-9.
Juvenile dermatomyositis (JDM) is a rare, often chronic autoimmune disease with onset during childhood. It is characterized by weakness in proximal muscles and pathognomonic skin rashes. Although the etiology remains unclear, it has been proposed that JDM is caused by a vasculopathy within the muscle tissue and multiple other organ systems of genetically susceptible individuals, possibly in response to environmental triggers. The goals of treatment include control of the underlying inflammatory myositis and prevention and/or treatment of complications (eg, contractures and calcinosis). Delayed treatment may lead to poorer outcome in terms of disease course and calcinosis. The course in JDM is variable. Monocyclic disease occurs in about one third of patients. These patients have a good response to standard therapy. Early recognition and aggressive immunosuppressive treatment result in improved prognosis.
幼年特发性皮肌炎(JDM)是一种罕见的、常为慢性的自身免疫性疾病,发病于儿童期。其特征为近端肌肉无力和具有特征性的皮疹。虽然病因尚不清楚,但据认为,JDM 是由肌肉组织和多个其他遗传易感个体的器官系统的血管病变引起的,可能是对环境触发因素的反应。治疗的目的包括控制潜在的炎症性肌炎以及预防和/或治疗并发症(例如挛缩和钙沉着症)。治疗延迟可能导致疾病过程和钙沉着症的预后较差。JDM 的病程多变。大约三分之一的患者发生单环疾病。这些患者对标准治疗有良好的反应。早期识别和积极的免疫抑制治疗可改善预后。